Clinical Research Directory
Browse clinical research sites, groups, and studies.
Validation of RCC Predicting Model With Emulated-target Trial
Sponsor: Peking University Third Hospital
Summary
This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
Official title: Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
4700
Start Date
2025-09-01
Completion Date
2027-08-01
Last Updated
2026-04-14
Healthy Volunteers
No
Conditions
Interventions
Model-guided adjuvant treatment
Initiation of standard adjuvant treatment within 12 weeks after surgery.
No adjuvant treatment
No initiation of adjuvant ICIs, radiotherapy, or targeted therapy at any point during follow-up prior to disease progression.
Locations (1)
Peking University Third Hospital
Beijing, Beijing Municipality, China